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Abstract
Buruli ulcer is a skin disease caused by Mycobacterium ulcerans that is spreading in tropical countries, with major public
health and economic implications in West Africa. Multi-analyte profiling of serum proteins in patients and endemic controls
revealed that Buruli ulcer disease down-regulates the circulating levels of a large array of inflammatory mediators, without
impacting on the leukocyte composition of peripheral blood. Notably, several proteins contributing to acute phase reaction,
lipid metabolism, coagulation and tissue remodelling were also impacted. Their down-regulation was selective and
persisted after the elimination of bacteria with antibiotic therapy. It involved proteins with various functions and origins,
suggesting that M. ulcerans infection causes global and chronic defects in the host’s protein metabolism. Accordingly,
patients had reduced levels of total serum proteins and blood urea, in the absence of signs of malnutrition, or functional
failure of liver or kidney. Interestingly, slow healers had deeper metabolic and coagulation defects at the start of antibiotic
therapy. In addition to providing novel insight into Buruli ulcer pathogenesis, our study therefore identifies a unique
proteomic signature for this disease.
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Introduction
Buruli ulcer disease (BUD) is a progressive ulceration of the skin
that results from infection with Mycobacterium ulcerans [1,2,3]. BUD
is associated with swamps, marshes and wetlands, with the most
affected countries in Western Africa. The disease classically starts
as a nodule, papule, plaque, or oedema that eventually breaks
down to form a painless, necrotic ulcer [4]. In the remote rural
areas where the disease is endemic, presentation and diagnosis is
often delayed and patients present with large ulcers, which cause
significant disability [5]. The recommended treatment for BUD
consists of streptomycin and rifampicin daily for eight weeks, with
grafting of larger lesions [6,7,8]. Although this is effective at killing
bacteria [9], 2–10% of individuals develop enlargement of lesions
upon treatment [10]. Skin wounds typically heal by progressing
through four consecutive phases including haemostasis, inflam-
mation, a proliferative stage with synthesis of extracellular matrix
(ECM) then a remodelling of the ECM. Whether and how
infection with M. ulcerans interferes with this healing process is
largely unknown [11]. To improve the current disease manage-
ment practices and develop personalized treatment plans, it is
crucial to better understand the pathophysiology of BUD and
identify biological correlates of healing.
M. ulcerans produces mycolactone, a macrolide cytotoxin with
immunosuppressive properties that underpins bacterial virulence
[12]. Sub-cutaneous injection of mycolactone in animal models
causes ulcerative skin lesions similar to those seen in BUD [13].
Contrary to wild-type M. ulcerans, mycolactone-deficient mutants
do not induce defective systemic production of IL-2 in animal
models, suggesting that mycolactone also impairs the generation of
cellular responses. In line with this hypothesis, mycolactone was
shown to suppress the expression of homing receptors and the
production of inflammatory mediators by lymphocytes, monocytes
and dendritic cells in vitro [14,15,16,17,18,19]. The mechanism by
which mycolactone modulates protein expression in a gene and
cell-specific manner in these immune cells nevertheless remains
unclear. The action of mycolactone differs from those of known
immunosuppressants, acting independently of the mammalian
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target of rapamycin (mTOR) [14,19]. Whether mycolactone also
alters protein expression in non-immune cells is not documented.
We reported previously that BU patients display a distinctive
profile of immune suppression, marked by the down-modulation
of selected chemokines and an impaired capacity of T cells to
produce cytokines upon stimulation ex vivo [20]. In the present
study, we performed a larger-scale profiling of serum proteins and
standard clinical analyses to improve our global understanding of
the effects of M. ulcerans infection on the physiology of the host.
Our results validate our previous observation that M. ulcerans
infection down-regulates the serum level of a large array of
proteins participating in immune responses. In addition, they show
that BUD represses the circulating level of key mediators of
coagulation and tissue remodelling. Although these alterations do
not impact on the host’s vital functions and immunity, they may
interfere with wound healing.
Materials and Methods
Ethics statement
The protocol of this study was approved by the ethics review
committees at the School of Medical Sciences, Kwame Nkrumah
University of Science and Technology, Kumasi, Ghana (CHRPE/
11/28/06). All adult subjects provided informed consent, and a
parent or guardian of any child participant provided informed
consent on their behalf. Informed consent was written (with thumb
print of parent or guardian in the case of children, depending on
literacy). Institutional review board gave approval to document
informed consent using thumb print for illiterate participants.
Study design
Patients were recruited in the middle forest belt of Ashanti
Region of Ghana, from Buruli ulcer endemic villages near Tepa
Government Hospital (Ahafo Ano North District), Agogo Presby-
terian Hospital and Ananekrom Health centre (Asante Akim
North District) and Nkawie Government Hospital (Atwima
Nwabiagya district), within 70 km of the regional capital Kumasi.
Patients were included in the study if they met the WHO clinical
case definition of M. ulcerans disease; were not pregnant; were not
receiving antibiotic treatment; had no history of tuberculosis,
leprosy, or liver, kidney, or hearing impairment. Age- and gender-
matched healthy controls from the same endemic area were
included. Three cohorts of patients and controls were constituted
for the purposes of this study that are described in Tables 1 to 4
and Table S1 in Text S1. Body mass index (BMI) was determined
in individuals of Cohort 2 according to international classification
(WHO global database, http://apps.who.int/bmi/).
Diagnosis and treatment
Fine needle aspirates were taken to confirm the clinical
diagnosis by PCR for the IS2404 repeat sequence characteristic
of M. ulcerans. Patients were started on streptomycin 15 mg/kg and
rifampicin 10 mg/kg treatment daily for 8 weeks, as recom-
mended by the WHO, at village health posts under direct
observation. Punch biopsy specimens of 4 mm diameter were also
stained for acid-fast bacilli and cultured on Lowenstein-Jensen
slopes, as previously described [21]. Patients with confirmed BUD
of less than 10 cm in maximum diameter provided 2 ml of serum.
All lesions had healed by 6 months and there were no recurrences
after 12 months upon completion of antibiotic therapy. Healthy
contacts from the same endemic areas also provided serum
samples to serve as a comparator.
FACS analysis
Whole blood was collected in heparin-containing tubes and
processed within the same day. Mix of fluorochrome-conjugated
antibodies were added to 100 ml whole blood, incubated for 15 min
in the dark, followed by 15 min in-dark red cell lysis with 1-step Fix/
Lyse solution (eBioscience). Cells were washed according to the
Table 1. Multi-analyte profiling (Cohort 1).
Healthy controls (n =14) Patients with BUD (n=20)
‘‘Fast healers’’ (n = 10) ‘‘Slow healers’’ (n = 10)
Age, median (range), years 15 (7–35) 32 (13–55) 10 (5–35)
Sex, no. male/no. female 7/7 4/6 6/4
Time to healing, median (range), weeks - 7 (4–12) 29 (16–48)
Ulcer category
I (lesion size ,5 cm in widest diameter) 6 6
II (lesion size ,15 cm in widest diameter) 4 4
Age, median (range), years 17 (5–55)
Time to healing, median (range), weeks 14 (4–48)
doi:10.1371/journal.pntd.0002786.t001
Author Summary
Buruli ulcer is a skin disease caused by inoculation of
Mycobacterium ulcerans bacteria, which is emerging in
tropical countries. Lesions typically start as nodules, which
eventually open to form progressive, non-healing wounds.
Although anti-mycobacterial antibiotics are efficient at
stopping the infection, ulcers often persist after comple-
tion of treatment for reasons that remain unclear. In the
present study, we performed a quantitative analysis of a
large array of proteins circulating in peripheral blood, with
the view to identifying biomarkers of disease progression
and wound chronicity. We found that Buruli ulcer disease
induces a unique signature of serum protein suppression
that outlasts the elimination of bacteria. Interestingly, the
initial levels of several of these proteins differed between
fast and slow healers, suggesting an association with
healing defects. Our results unravel an unexpected feature
of Buruli ulcer disease and show that M. ulcerans infection
has global and durable effects on the host’s protein
metabolism.
Serum Protein Profiling in Buruli Ulcer Disease
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manufacturer’s protocol and analyzed on a BD FACSCalibur. Anti-
CD4-FITC (555339), anti-CD8-FITC (345772), anti-CD19-FITC
(345788), anti-CD62L-PE (555544), anti-CD45RA-PE (555489)
and anti-CD3-APC (555335) were from BD Pharmingen.
Blood cell counts and chemistry tests
Absolute counts of neutrophils, monocytes, lymphocytes and
eosinophils in fresh peripheral blood were determined with a
hematology analyzer. Blood glucose, blood lipids (total cholesterol,
triglyceride, high and low density lipoprotein HDL and LDL);
liver function indicators (Alanine aminotransferase (ALT), alkaline
phosphatase (ALP), Gamma-glutamyl transferases (GGT), Total
protein, Albumin, Globulin, total/direct/indirect Bilirubin) and
renal function indicators (urea, creatinine, blood urea nitrogen to
creatinine ratio) were measured in serum with standard hospital
instrumentation. Individuals fasted for a minimum of 12 h before
LDL, triglyceride or blood glucose measurements. Non-esterified
fatty acids (NEFA) were assessed in serum with the Free fatty acids,
half-micro test (Roche).
Multi-analyte profiling of serum proteins
Serum samples (100 ml) were sent on dry ice to Rules-Based
Medicine Inc. (Austin, USA) for quantitative measurement of 88
proteins (Human Multi-Analyte Profile (MAP) v1.6). Details on the
methodology used by this company can be found at www.
rulesbasedmedicine.com. Briefly, samples were incubated with a
mixture of fluorescently labeled microspheres, with each type
conjugated to a different capture antibody. A mixture of
biotinylated secondary antibodies was then added to label bead-
captured antigen, then streptavidin-phycoerythrin added to the
complex. Flow cytometry analysis with a Luminex 100 flow
analyzer was used to quantify fluorescence signals for each
antigen. Purified antigen standards were included to relate bead-
based fluorescence to antigen concentration. A ‘‘Lowest Detect-
able Dose’’ (LDD) was also reported for each antigen that
corresponds to mean fluorescence signal of 20 blanks +3 SD. The
LDD is considered the lower limit at which the system can
accurately calculate the concentration of an experimental sample,
with confidence that the concentration is higher than that of a
blank sample. We chose to keep only variables for which .50%
measures were above the LDD in one of the control or patient
group. This resulted in retention of 71 out of the 88 variables
(Fig. 1). The lower assay limit (LAL) is each assay’s working
sensitivity as defined by the lowest concentration calibrator found
on the standard curve that provides a quantifiable measurement
above background. The LAL is typically lower than the LDD.
Values below the LAL were replaced with a value that was 50% of
the lowest value measured in the data set. Values above the
maximum value of the standard curve were set at this maximum.
Statistical analysis
Multivariate data analysis was performed with the SIMCA
13 software (Umetrics, Sweden) to predict clinical status based
on protein signatures in 1) BUD patients before antibiotic
treatment (BUD 0) versus healthy controls, 2) BUD patients 4
weeks after the end of the 8 week antibiotic treatment (BUD
12) versus healthy controls, 3) BUD 0 versus BUD 12 and 4)
fast versus slow healers. We used conventional Principal
Component Analysis (PCA) to gain a first insight into the
general distribution of our dataset and detect outliers. In
complement, Orthogonal Partial Least Squares-Discriminant
Analysis (O-PLS-DA) was performed to identify the variables
contributing to group classification [22]. The quality of each
model was assessed by calculation of Fit (R2) and prediction
ability (Q2) values. To further characterize univariate differ-
ences between controls, BUD 0 and BUD 12 patients, the non-
parametric Wilcoxon ranksum (Mann-Whitney) test was used.
Paired samples for BUD patients at week 0 and week 12 were
compared using the Wilcoxon signed rank test. As this led to
performing 71 tests for each comparison, we adjusted for
multiple testing by defining as significant all p-values,0.05
that also guaranteed a false discovery rate (FDR) under 1%
[23]. Univariate analysis and multiple testing adjustments were
performed using R software (version 2.13.2, R Development
Core Team, R Foundation for Statistical Computing, Vienna,
Austria) and package QVALUE v1.0 [24]. The GraphPad
Prism software (v5.0d, La Jolla, CA) was used for box-and-
whisker plot representation, with outlier cut-off determined by
Tukey’s test. Outliers were kept in all statistical analyses and
are represented by dots in box-and-whisker plots.
Table 2. Complete blood count and blood chemistry (Cohort 2).
Complete blood count and blood chemistry
(liver and renal function tests, blood lipids) Healthy controls (n =20) Patients with BUD (n=44)
Age, median (range), years 14.5 (8–50) 16 (6–61)
Sex, no. male/no. female 7/13 18/26
doi:10.1371/journal.pntd.0002786.t002
Table 3. FACS analysis (Part of Cohort 2).
Healthy controls (n=9) Patients with BUD (n=10)
Age, median (range), years 13 (8–35) 25 (12–47)
Sex, no. male/no. female 3/6 3/7
Ulcer category
I (lesion size ,5 cm in widest diameter) 9
II (lesion size ,15 cm in widest diameter) 1
doi:10.1371/journal.pntd.0002786.t003
Serum Protein Profiling in Buruli Ulcer Disease
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Results
Suppression of multiple serum proteins in BUD
Serum harvested from 20 patients at the time of BUD diagnosis
(BUD 0), and 4 weeks after completion of antibiotic therapy (i.e.
week 12, BUD 12) were compared to those of healthy controls
from the same endemic community (Table 1). Samples were
subjected to a multi-analyte profiling technology allowing for the
quantitative and simultaneous determination of 88 proteins
reflecting inflammation, lipid metabolism, coagulation, tissue
remodelling and other pathways. Of the 88 targeted proteins, 71
met the inclusion criteria for further analysis (see Materials and
Methods). PCA of the selected analytes resulted in a clear
separation between BUD patients and healthy controls (R2 = 0.50;
Q2= 0.41), but not between patients at the beginning or end of
antibiotic therapy (unshown data). O-PLS-DA improved the
separation of controls versus BUD 0 (R2= 0.96; Q2= 0.92) and
controls versus BUD 12 (R2= 0.96; Q2= 0.88) (Fig. 2A) but failed
to better discriminate BUD 0 from BUD 12, suggesting that BUD
induces alterations in serum proteins that are maintained after the
end of antibiotic treatment.
Accordingly, all analytes distributed along the diagonal of a
BUD 0/BUD 12 Shared and Unique Structures (SUS)-plot
(Fig. 2B). Notably, a large proportion of the dots were
concentrated in the lower left quadrant, indicating that BUD
has a suppressive effect on most tested proteins, irrespective of
their functional category. Univariate analyses confirmed that 44/
71 serum proteins were down-modulated in BUD 0 compared to
controls (Fig. 1). Because our cohorts of patients and controls did
not match perfectly with regard to age, we verified potential links
between variables and age a posteriori. This analysis identified 14
variables correlating negatively with age in controls, according to
Spearman’s test (Coefficient ,20.6) (Fig. 1 and Figure S1 in Text
S1). Their down-regulation in patients may be due to an age bias
and must be interpreted with caution. With regard to the variable
with the highest correlation coefficient, MCP-1, we found that
protein levels were not associated with age in BUD patients at
Week 0 (Spearman coefficient R= 0.02). In a logistic regression
model where BUD status was explained by MCP-1 levels at week
0, age was not significantly associated to disease and its
introduction did not modify the relationship between BUD status
and MCP-1 levels. Together, these findings thus indicated that the
relationship between BUD and MCP-1 levels at week 0 was
unlikely to be confounded by age. Notably, 43 of the 44 proteins
that were down-regulated by BUD were still suppressed after 12
weeks, that is one month after completion of antibiotic therapy.
Amongst the variations contributing the most to differentiate BUD
patients from controls was the suppression of TNF-b, interleukin
(IL)-3 and IL-13 and the induction of metalloproteinase MMP-2,
damage associated molecule EN-RAGE (S100A12) and coagula-
tion inhibitor A2-Macroglobulin (Fig. 1 and Fig. 2B).
Broad but uneven down-modulation of inflammatory
mediators in the peripheral blood of patients with BUD
The presence of an immunosuppressive signature in BUD,
marked by the down-modulation of serum Macrophage inflam-
matory protein-1-beta (MIP-1b), Monocyte chemotactic protein-1
(MCP-1) and Interleukin (IL)-8 has been previously reported [20].
Although IL-8 was not significantly modulated in the present
study, MIP-1b and MCP-1 were lowered in BUD 0, compared to
controls (Figure S1 in Text S1). Furthermore, other inflammatory
chemokines, such as the Regulated upon activation normal T cell
expressed and secreted RANTES, the Macrophage-derived
chemokine MDC and the Epithelial neutrophil-activating protein
78 (ENA-78), and a number of cytokines: IL-1a, IL-3, IL-5, IL-7,
IL-10, IL-12p40/p70, IL-13, IL-15, IL-18, Tumor necrosis factor
alpha and beta (TNF-a and -b), IL-10 and Stem cell factor SCF
were reduced in patients (Figure S1 in Text S1). A significant
decrease in the concentrations of soluble CD40, CD40 ligand
(CD40L) and Beta-2-microglobulin (B2-M) was also observed,
indicative of systemic defects in T cell activation. Longitudinal
analyses of TNF-a and MCP-1 levels in serum at 0, 6, 12 and 32
weeks post diagnosis with the Luminex approach confirmed this
general trend, in spite of important kinetic and inter-individual
variations (as shown in Fig. 3A for TNF-a). Of note, BUD-
associated defects affected the B cell compartment, as evidenced
by the reduced levels of Immunoglobulin (Ig) A and IgM (Figure
S1 in Text S1). However, IgE, IL-16 and Myeloperoxydase (MPO)
were unchanged and EN-RAGE was up-regulated in patients,
showing that the immunosuppressive effect of BUD is not uniform.
To determine if the down-modulation of lymphocyte-derived
cytokines, chemokines and Igs in BUD patients could be due to
infection-induced cell death, we recruited 10 additional patients
and healthy controls (Table 3) and assessed CD4+, CD8+ and
CD19+ peripheral blood lymphocytes by means of complete blood
count and fluorescence activated cell sorting (FACS). Since CD62-
L expression was shown to decrease in T cells upon exposure to
mycolactone [17], this homing molecule was also included in the
staining panel. No significant difference in the mean expression of
CD4, CD8 or CD62-L by T cells nor in the relative abundance of
lymphocytes expressing these receptors could be demonstrated in
BUD patients (Figure S2 in Text S1). A minor increase in the
mean expression of CD19 in B cells was observed in patients,
which might be due to the presence of two outliers. While one
would expect variations in the numbers of white blood cells in
infected individuals, absolute counts of neutrophils, monocytes and
eosinophils were comparable in BUD patients and controls
(Fig. 3B). The total number of lymphocytes was slightly reduced
Table 4. NEFA assay (Cohort 3).
Healthy controls (n =9) Patients with BUD (n=15)
Age, median (range), years 10 (7–35) 12 (5–32)
Sex, no. male/no. female 5/4 8/7
Time to healing, median (range), weeks - 18 (4–40)
Ulcer category
I (lesion size ,5 cm in widest diameter) 11
II (lesion size ,15 cm in widest diameter) 3
doi:10.1371/journal.pntd.0002786.t004
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in patients, but remained within normal values (1000–3700 cells
per ml). In conclusion, BUD alters durably the circulating levels of
a large array of inflammatory mediators without perturbing the
composition of peripheral blood leukocyte populations.
Abnormal metabolic responses to M. ulcerans infection
Infection with pathogenic microorganisms typically induces the
production of pro-inflammatory cytokines by innate immune cells,
which in turn triggers a reprogramming of protein synthesis in the
liver. This so-called ‘‘acute phase reaction’’ (APR) is thought to
result primarily from the activation of hepatic receptors by TNF-a,
IL-1 and IL-6, and entails the active production and release in the
peripheral circulation of proteins trapping micro-organisms,
activating complement and modulating the host’s immune
response. Since IL-1b and IL-6 were unchanged and TNF-a was
suppressed in patients, we examined the impact of the disease on
Figure 1. Univariate analysis of the measured serum proteins in healthy donors (Ctrl) and BUD patients at week 0 (BUD 0) or week
12 (BUD 12) p#0.001 (***); p#0.05 (**); p#0.01 (*). The u symbol shows the analytes associated with age, according to Spearman (Coefficient
,20.6).
doi:10.1371/journal.pntd.0002786.g001
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acute phase reactants. In spite of the presence of progressive
lesions in their skin, BUD patients at Week 0 (BUD 0) and controls
had equivalent mean levels of C-reactive protein (CRP) and
Complement Factor 3 (C3), while Fibrinogen, Plasminogen-
activator inhibitor type 1 (PAI-1), Serum amyloid P-component
(SAP), and Alpha-1 antitrypsin (A1-AT) were in fact suppressed by
infection (Fig. 1 and Figure S1 in Text S1). The proteinase
inhibitor alpha-2 macroglobulin (A2-M) was the only exception to
this rule.
To investigate the possibility that liver functionality was altered
in patients, we conducted a series of biochemical assays in the
serum of patients and controls from Cohort 2. ALT, ALP and
bilirubin (both total, direct and indirect) were down-regulated in
patients while GGT were unchanged (Fig. 4 and unshown data),
ruling out the possibility that BUD causes liver damage. Albumin
is exclusively produced by the liver and negatively regulated
during APR. Surprisingly in the absence of positive acute phase
reactants, the serum levels of albumin were reduced in patients.
Consistent with the down-modulation of alpha-, beta- and
gamma-globulins (A1-AT, B2-M and Igs), BUD patients also
had reduced globulin levels, compared to controls. As a result of
the decrease in both albumin and globulins, patients displayed
significantly lower levels of total serum proteins. However their
mean concentrations of albumin, globulin, total proteins and
albumin/globulin ratios remained within reference range. Blood
urea and creatinine were diminished in patients, while the blood
urea nitrogen/creatinine ratio remained normal, arguing against
acute kidney failure or dehydration problems (Fig. 4). Together,
these data suggested that BUD impacts on the host’s metabolism
of protein, without damaging liver, kidney or muscles.
Alterations in blood lipid transporters and free fatty acids
Our screen also identified perturbations in proteins that are not
involved in immune responses and APR, such as regulators of lipid
metabolism and transport. Apolipoprotein (Apo) A-I, Apo C-III,
Apo H, Fatty acid binding protein (FABP) and Insulin were
suppressed by 50% on average in BUD patients, while Lipoprotein
(Lp) was unchanged (Fig. 1 and Figure S1 in Text S1). To evaluate
the possible impact of these changes on lipid generation and
transport, we assessed blood lipids and lipoproteins in patients and
controls (Tables 2 and 4). Total cholesterol, HDL, LDL and
triglycerides were unaffected by the disease (Fig. 5A). In contrast,
the serum level of non-esterified fatty acids (NEFA) was
significantly reduced in BUD patients, with minimal values
Figure 2. Suppression of multiple serum proteins in patients with BUD. A) O-PLS-DA of serum protein levels in healthy donors (Ctrl) versus
BUD patients at week 0 (BUD 0, left) or week 12 (BUD 12, right). Score plots displaying predictive t[1] versus orthogonal tO[1] components are shown,
with 95% confidence ellipses (based on Hotelling’s T2 statistic) showing the absence of outliers. B) SUS-plot resulting from these O-PLS-DA models.
Variables situated along the indicated diagonal are comparably modulated in BUD 0 and BUD 12, compared to Ctrl. The more reliable (pcorr[1] close
to 21 and +1) are labelled.
doi:10.1371/journal.pntd.0002786.g002
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detected 3 months post diagnosis and restoring after 8 months
(Fig. 5B). Since NEFAs are water-insoluble and transported in the
circulatory system bound to albumin, their lower serum concen-
tration may reflect the reduced availability of their transporter.
Modulation of tissue remodelling markers
Consistent with the destruction of cutaneous and subcutaneous
tissues by M. ulcerans, a number of markers of tissue remodelling
were altered in patients. The circulating concentrations of matrix
metalloproteinase-3 (MMP-3) and vascular endothelial growth
factor (VEGF), which are both crucial for connective tissue
remodelling and wound repair, were stably down-regulated by
BUD (Fig. 1 and Figure S1 in Text S1). However MMP-2, which
also contributes to regulation of vascularisation and inflammation,
was modulated in the opposite direction. EN-RAGE, another
important regulator of vascular remodelling, was also up-regulated
by M. ulcerans infection.
Differential inflammatory and metabolic profiles in faster
healing patients
To identify biological correlates of healing, we then subjected
our data to a multivariate analysis comparing serum protein levels
measured at the time of inclusion in antibiotic therapy in ‘‘fast
healers’’ (FH) and ‘‘slow healers’’ (SH). For this purpose, a cut-off
healing time of 12 weeks was chosen, as it divided the BUD cohort
into two sub-groups of 10 patients that were comparable in terms
of gender ratio and category of lesion (Table 1). O-PLS-DA of
serum proteins resulted in a clear separation between FH and SH
(R2= 1.00; Q2= 0.43) (Fig. 6A), but not between FH or SH
between week 0 and week 12 (unshown data). Compared to FH,
SH displayed relatively higher initial levels of TNF-b and MCP-1;
and lower levels of Factor VII and Apo H (Fig. 6B). Although
these initial differences between fast and slow healers must be
confirmed with larger cohorts of patients, the data in Figure 6
suggest that impaired healing is associated with distinct inflam-
matory and coagulation defects.
Discussion
Our multi-analyte profiling of the serum of BUD patients
revealed the suppression of a large array of circulating proteins.
The analytes targeted by our study were representative of the
major categories of serum proteins, and their global suppression
reflected by a 10% decrease in total protein. Since some proteins
were up-regulated by the disease, the down-regulatory effect of
Figure 3. Down-modulated inflammatory mediators but normal leukocyte numbers in the peripheral blood of BUD patients. A)
Evolution of the concentration of TNF-a in the serum of BUD patients, at the time of diagnosis (0 weeks) and 6, 12 and 32 weeks later, compared to
healthy controls (Ctrls). The left panel shows the distribution of TNF-a concentrations at given time points as Box and Whiskers. The right panel shows
the longitudinal variations of TNF-a in individual patients. (B) Leukocyte concentrations, presented as Box and Whiskers, in the blood of BUD patients
and controls (Ctrl), as determined by complete blood counts.
doi:10.1371/journal.pntd.0002786.g003
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BUD is unlikely to be due to plasma volume expansion. The
absence of obvious swelling in patients, and the fact that their
mean weight, height, BMI, heart rate and blood pressure were
comparable to those of controls (Table S1 in Text S1, Cohort 2)
also argue against this possibility. Invasion of pathogenic
microorganisms or tissue injury typically induce a localized
inflammation triggering the production of cytokines, chemokines,
immunoglobulins by the immune system and acute phase proteins
by the liver. This is exemplified by the potent pro-inflammatory
cytokine and acute phase responses that follow infection with M.
tuberculosis, and their reduction upon antibiotic treatment [25].
Severe burns cause acute inflammation and production of CRP,
accompanied with extensive muscle catabolism and protein
anabolism in the wound [26,27]. In spite of the presence of
proliferating bacilli and necrotic material in Buruli ulcers, we
found no evidence of such inflammatory responses and acute
phase reaction in patients, suggesting that M. ulcerans successfully
evades immune recognition. To our knowledge, the combined
suppression of inflammatory mediators and major serum proteins
is a unique feature of M. ulcerans infection.
We previously reported that BUD patients display a distinctive
signature of chemokine suppression in their peripheral blood [20].
Here, we validate this observation in independent cohorts of
patients and endemic controls, and extend the list of inflammatory
mediators that are down-regulated by M. ulcerans infection. BUD
patients showed a broad inhibition of the circulating levels of
multiple cytokines, chemokines and Igs. In contrast, the granulo-
cyte-derived EN-RAGE was induced in patients with BU and
down-modulated in 14/20 patients undergoing treatment. As
previously reported for a number of inflammatory disorders, this
member of the S100 family of calcium-binding proteins may be of
clinical value in the assessment of BUD [28]. With the exception of
EN-RAGE, our data support the lack of inflammation surround-
ing necrotic lesions [4] and the functional defects of circulating T
lymphocytes in BUD patients [20,29]. The concentration and
viability of monocytes, neutrophils, T and B cell populations were
intact in the peripheral blood of BUD patients, showing that M.
ulcerans infection does not impair innate and acquired immune
responses by depleting these immune cell subsets.
Importantly, BUD patients do not show increased susceptibility
to microbial infections [2]. In the mouse model, the control of
Listeria monocytogenes infection is not altered by co-infection with M.
ulcerans [30]. The immunosuppressive signature in the peripheral
blood of patients with BUD is therefore not indicative of an
immunodeficient status. Our longitudinal analysis of individual
patients with BUD showed that down-regulation of TNF-a is
incomplete and fluctuant during treatment (Fig. 3A), suggesting
that inflammation is tuned down by infection but not abolished.
Intriguingly, immune modulation persisted for weeks after the
elimination of M. ulcerans bacilli with antibiotic treatment.
Structurally intact mycolactone has been found in significant
amounts in ulcer exudates after completion of antibiotic therapy
[31]. Since mycolactone diffuses from infected skin into the
peripheral blood and accumulates in internal organs such as spleen
and liver [32], the long-lasting down-regulation of inflammatory
markers in the peripheral blood of treated patients may thus reflect
the slow release of this compound into the circulation. Recent
progresses in the techniques allowing mycolactone extraction and
Figure 4. Abnormal metabolic responses to M. ulcerans infection. Effect of BUD on the serum level of various indicators of liver and renal
function is shown. Data are presented as Box and Whiskers in Ctrl and BUD patients. *p,0.01, **p,0.005, ***p,0.001, NS: not significant.
doi:10.1371/journal.pntd.0002786.g004
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quantification from peripheral blood and tissues may help address
this hypothesis [33,34].
Inflammation is highly connected to the biology of adipose
tissues [35]. At the tissue level, this is illustrated by the localized
infiltration of inflammatory cells into the fat tissues of obese
subjects. At the systemic level, obesity is associated with elevated
pro-inflammatory cytokines TNF-a and IL-6, NEFA and basal
concentrations of insulin. Interestingly, BUD patients had an
opposite phenotype, with lower TNF-a, insulin and NEFAs.
Adipocytes produce a vast array of signalling proteins including
VEGF, TNF-a, Adiponectin, A2M, VCAM-1, CRP, PA1, MCP-
1, RANTES and TIMPs, all of which were down-modulated by
the disease. It will be interesting to determine if these alterations
are the direct consequences of a selective inhibition of protein
synthesis by mycolactone in adipocytes, as previously shown in
monocytes [19]. Alternatively, as BUD affects the circulating levels
of proteins produced by various tissues including the liver and
muscle tissues, they may reflect a central regulation of the host’s
metabolism via hormones.
Protein requirement increases during wound healing, and
malnutrition is a risk factor for pressure ulcers. As a negative acute
phase reactant that is affected by inflammation, albumin typically
correlates inversely with infection, trauma, surgery, burns, or
oedema. Decreased levels of serum albumin is considered an
indicator of morbidity and mortality, while increased levels reflect
improvement in clinical status [36]. In the present work, we
Figure 5. Decreased levels of free fatty acids in the peripheral blood of patients with BUD. A) Concentration of blood lipids in patients
and controls (Ctrl). B) Serum levels of NEFA in patients at week 0, 6 12 or 32, and in controls (Ctrl). Data are presented as Box and Whiskers,
***p,0.001, NS: not significant.
doi:10.1371/journal.pntd.0002786.g005
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observed a significant reduction in the mean serum albumin and
total protein levels of BUD patients. Although none of the
individuals recruited in this study showed severe signs of malnutri-
tion, 42–50% of patients and controls were mildly to severely thin,
according to WHO criteria. Since these proportions
were comparable in patients and controls, it is unlikely that
poor nutritional status is a risk factor for BUD. However, research
into the nutritional requirements of patients with pressure ulcers
suggests that it may impair BU healing. Based on our results, it
would be useful to determine if M. ulcerans infection impairs body
protein anabolism.
Our comparison of good vs. bad responders suggested that slowly
healing patients have a differential profile of alterations in the
inflammatory and coagulation pathways at the start of antibiotic
therapy. Since the proportion of pre-ulcerative and ulcerative forms
at inclusion was comparable in fast and slow healers, and both
groups had comparable mean diameter of lesion (Table S1 in Text
S1, Cohort 1), these differences cannot be explained by differential
pathogenesis. Whether differences in the inflammatory and
coagulation pathways exist before infection and predispose to M.
ulcerans infection will require further work. Yet, our observation that
cytokines and chemokines that are down-regulated by BUD slowly
recover normal values (Fig. 2A and our previous findings [20])
argues against this hypothesis. Since their return to normal level
does not coincide with the end of antibiotic treatment nor ulcer
resolution, we propose that alterations is serum proteins of treated
patients reflect the persistence of mycolactone or the long-lasting
effects of infection-induced perturbations in the host’s metabolism.
Supporting Information
Text S1 Table S1: Information on each individual recruited in
this study. Figure S1: Modulation of serum proteins by BUD. Data
obtained for each of the 71 analytes are presented as Box and
Whiskers in healthy controls (Ctrl) and patients at the beginning of
antibiotic therapy (BUD 0) or 4 weeks after completion of
treatment (BUD 12). Figure S2: FACS analysis of B and T cell
populations in the peripheral blood of patients with BUD,
compared to healthy controls (Ctrl). Data are percentage of
lymphocytes (as gated on FSC/SSC) and mean fluorescence
intensities (MFI) for CD4, CD8, CD19 and CD62-L positive cells,
presented as Box and Whiskers *p,0.01, **p,0.005, ***p,0.001,
NS: not significant.
(PPT)
Figure 6. Differential protein signature in fast and slow healers. A) O-PLS-DA of serum protein levels in fast and slow healers, before the
beginning of antibiotic therapy. The score plot for this model (predictive t[1] versus orthogonal tO[1]) with a 95% confidence ellipse are shown. B) S-
plot illustrating the modelled covariance (p[1]-axis) and correlation (pcorr[1]-axis) of variables in FH and SH. The p[1]-axis describes the magnitude of
each variable, while the pcorr[1]-axis represents the reliability of each variable (between +/21). The most discriminating variables, at both extremities
of the X-Y diagonal, are labelled.
doi:10.1371/journal.pntd.0002786.g006
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